{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:14:49Z","timestamp":1779340489562,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1124\/molpharm.124.000868","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T22:05:11Z","timestamp":1715033111000},"page":"33-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circumvention of Topoisomerase II\u03b1 Intron 19 Intronic Polyadenylation in Acquired Etoposide-Resistant Human Leukemia K562 Cells"],"prefix":"10.1016","volume":"106","author":[{"given":"Xinyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessika","family":"Carvajal-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0381-9356","authenticated-orcid":false,"given":"Junan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor A.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-573X","authenticated-orcid":false,"given":"Jack C.","family":"Yalowich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-8741","authenticated-orcid":false,"given":"Terry S.","family":"Elton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.124.000868_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1124\/molpharm.124.000868_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cell.2019.04.046","article-title":"A Deep Neural Network for Predicting and Engineering Alternative Polyadenylation","volume":"178","author":"Bogard","year":"2019","journal-title":"Cell"},{"key":"10.1124\/molpharm.124.000868_bib3","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1073\/pnas.0803513105","article-title":"Topoisomerase levels determine chemotherapy response in vitro and in vivo","volume":"105","author":"Burgess","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000868_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semcdb.2019.05.006","article-title":"Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines","volume":"98","author":"Capel\u00f4a","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"10.1124\/molpharm.124.000868_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","article-title":"New mechanistic and functional insights into DNA topoisomerases","volume":"82","author":"Chen","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/molpharm.124.000868_bib6","first-page":"237","article-title":"Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butyric acid","volume":"41","author":"Cioe","year":"1981","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.124.000868_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-016-2999-1","article-title":"Molecular chess? Hallmarks of anti-cancer drug resistance","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1124\/molpharm.124.000868_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/nar\/gkn937","article-title":"The DNA cleavage reaction of topoisomerase II: wolf in sheep\u2019s clothing","volume":"37","author":"Deweese","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/molpharm.124.000868_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000868_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2019.1621292","article-title":"Topoisomerase II inhibitors in AML: past, present, and future","volume":"20","author":"Economides","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/molpharm.124.000868_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr Drug Metab"},{"key":"10.1124\/molpharm.124.000868_bib12","first-page":"161","article-title":"Effects of DNA topoisomerase II\u03b1 splice variants on acquired drug resistance","volume":"3","author":"Elton","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"10.1124\/molpharm.124.000868_bib13","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.3390\/cancers14133148","article-title":"Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR\/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase II\u03b1","volume":"14","author":"Elton","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/molpharm.124.000868_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphar.2013.00089","article-title":"Mechanisms regulating resistance to inhibitors of topoisomerase II","volume":"4","author":"Ganapathi","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yjmcc.2014.08.007","article-title":"Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides","volume":"76","author":"Gong","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/molpharm.124.000868_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4939-6817-6_12","article-title":"Regulation of Isoform Expression by Blocking Polyadenylation Signal Sequences with Morpholinos","volume":"1565","author":"Gong","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1124\/molpharm.124.000868_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","article-title":"OpenComet: an automated tool for comet assay image analysis","volume":"2","author":"Gyori","year":"2014","journal-title":"Redox Biol"},{"key":"10.1124\/molpharm.124.000868_bib18","first-page":"1707","article-title":"Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line","volume":"55","author":"Harker","year":"1995","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.124.000868_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/molpharm.120.000173","article-title":"CRISPR\/Cas9 Genome Editing of the Human Topoisomerase II\u03b1 Intron 19 5\u2032 Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells","volume":"99","author":"Hernandez","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265794","article-title":"Use of CRISPR\/Cas9 with homology-directed repair to silence the human topoisomerase II\u03b1 intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells","volume":"17","author":"Hernandez","year":"2022","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.124.000868_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1124\/molpharm.124.000868_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tig.2019.05.005","article-title":"Transcriptional Control by Premature Termination: A Forgotten Mechanism","volume":"35","author":"Kamieniarz-Gdula","year":"2019","journal-title":"Trends Genet"},{"key":"10.1124\/molpharm.124.000868_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1124\/jpet.116.237107","article-title":"Alternative RNA processing of topoisomerase II\u03b1 in etoposide-resistant human leukemia K562 cells: intron retention results in a novel C-terminal truncated 90-kDa isoform","volume":"360","author":"Kanagasabai","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.124.000868_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/mol.117.111567","article-title":"The novel C-terminal truncated 90-kDa isoform of topoisomerase II\u03b1 (TOP2\u03b1\/90) is a determinant of etoposide resistance in K562 leukemia cells via heterodimerization with the TOP2\u03b1\/170 isoform","volume":"93","author":"Kanagasabai","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/mol.119.118315","article-title":"hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II\u03b1 in Human Leukemia K562 Cells with Acquired Resistance to Etoposide","volume":"97","author":"Kania","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-1119(98)00468-5","article-title":"Structural organization of the human TOP2A and TOP2B genes","volume":"221","author":"Lang","year":"1998","journal-title":"Gene"},{"key":"10.1124\/molpharm.124.000868_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/deacc2fd-665b-4736-b668-dc69a38bb4f9","article-title":"Structural basis of gate-DNA breakage and resealing by type II topoisomerases","volume":"5","author":"Laponogov","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.124.000868_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-018-0465-8","article-title":"Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia","volume":"561","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000868_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jbiotec.2016.11.011","article-title":"Enhanced CRISPR\/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA","volume":"241","author":"Liang","year":"2017","journal-title":"J Biotechnol"},{"key":"10.1124\/molpharm.124.000868_bib30","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1096\/fj.06-7434com","article-title":"Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity","volume":"21","author":"Lorenz","year":"2007","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.124.000868_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mrfmmm.2010.08.008","article-title":"Accumulation of true single strand breaks and AP sites in base excision repair deficient cells","volume":"694","author":"Luke","year":"2010","journal-title":"Mutat Res"},{"key":"10.1124\/molpharm.124.000868_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.tcb.2017.04.006","article-title":"Mining for Micropeptides","volume":"27","author":"Makarewich","year":"2017","journal-title":"Trends Cell Biol"},{"key":"10.1124\/molpharm.124.000868_bib33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1124\/molpharm.124.000868_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-genet-120116-024704","article-title":"Regulation by 3\u2032-untranslated regions","volume":"51","author":"Mayr","year":"2017","journal-title":"Annu Rev Genet"},{"key":"10.1124\/molpharm.124.000868_bib35","first-page":"193","article-title":"Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines","volume":"9","author":"Mo","year":"1997","journal-title":"Oncol Res"},{"key":"10.1124\/molpharm.124.000868_bib36","first-page":"11497","article-title":"The changing paradigm of intron retention: regulation, ramifications and recipes","volume":"47","author":"Monteuuis","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/molpharm.124.000868_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nature20160","article-title":"Intronic polyadenylation of PDGFR\u03b1 in resident stem cells attenuates muscle fibrosis","volume":"540","author":"Mueller","year":"2016","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000868_bib38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.124.000868_bib39","first-page":"179","article-title":"The comet assay. An overview of techniques","volume":"203","author":"Olive","year":"2002","journal-title":"Methods Mol Biol"},{"key":"10.1124\/molpharm.124.000868_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9","volume":"533","author":"Paquet","year":"2016","journal-title":"Nature"},{"key":"10.1124\/molpharm.124.000868_bib41","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.2174\/092986712802002473","article-title":"Cancer resistance to type II topoisomerase inhibitors","volume":"19","author":"Pilati","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1124\/molpharm.124.000868_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1124\/molpharm.124.000868_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrd3404","article-title":"Interfacial inhibitors: targeting macromolecular complexes","volume":"11","author":"Pommier","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/molpharm.124.000868_bib44","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1124\/molpharm.124.000868_bib45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nbt.3481","article-title":"Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA","volume":"34","author":"Richardson","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1124\/molpharm.124.000868_bib46","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/0006-2952(93)90643-B","article-title":"Altered gene expression in human leukemia K562 cells selected for resistance to etoposide","volume":"46","author":"Ritke","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/bjc.1994.131","article-title":"Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells","volume":"69","author":"Ritke","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1124\/molpharm.124.000868_bib48","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.124.000868_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2388","article-title":"Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity","volume":"19","author":"Schmidt","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/molpharm.124.000868_bib50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1124\/molpharm.124.000868_bib51","doi-asserted-by":"crossref","first-page":"19482","DOI":"10.1038\/s41598-021-98965-y","article-title":"Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair","volume":"11","author":"Schubert","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.124.000868_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/molpharm.124.000868_bib53","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41467-018-04112-z","article-title":"Widespread intronic polyadenylation diversifies immune cell transcriptomes","volume":"9","author":"Singh","year":"2018","journal-title":"Nat Commun"},{"key":"10.1124\/molpharm.124.000868_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/molpharm.124.000868_bib55","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/ijms22020863","article-title":"Regulation of Kv11.1 Isoform Expression by Polyadenylate Binding Protein Nuclear 1","volume":"22","author":"Stump","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/molpharm.124.000868_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molcel.2017.03.016","article-title":"Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a","volume":"66","author":"Swarts","year":"2017","journal-title":"Mol Cell"},{"key":"10.1124\/molpharm.124.000868_bib57","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.molcel.2018.11.021","article-title":"Mechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a","volume":"73","author":"Swarts","year":"2019","journal-title":"Mol Cell"},{"key":"10.1124\/molpharm.124.000868_bib58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tibs.2013.03.005","article-title":"Alternative cleavage and polyadenylation: the long and short of it","volume":"38","author":"Tian","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"10.1124\/molpharm.124.000868_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrm.2016.116","article-title":"Alternative polyadenylation of mRNA precursors","volume":"18","author":"Tian","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/molpharm.124.000868_bib60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1101\/gr.5532707","article-title":"Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing","volume":"17","author":"Tian","year":"2007","journal-title":"Genome Res"},{"key":"10.1124\/molpharm.124.000868_bib61","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1096\/fj.07-8809com","article-title":"Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta","volume":"21","author":"Thomas","year":"2007","journal-title":"FASEB J"},{"key":"10.1124\/molpharm.124.000868_bib62","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.1073\/pnas.85.19.7177","article-title":"Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22","volume":"85","author":"Tsai-Pflugfelder","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.124.000868_bib63","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/acs.biochem.1c00240","article-title":"Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors","volume":"60","author":"Vann","year":"2021","journal-title":"Biochemistry"},{"key":"10.1124\/molpharm.124.000868_bib64","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.molcel.2011.08.009","article-title":"Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation","volume":"43","author":"Vorlov\u00e1","year":"2011","journal-title":"Mol Cell"},{"key":"10.1124\/molpharm.124.000868_bib65","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/molpharm.124.000868_bib66","first-page":"209","article-title":"Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells","volume":"2","author":"Woessner","year":"1991","journal-title":"Cell Growth Differ"},{"key":"10.1124\/molpharm.124.000868_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/1066527041410418","article-title":"Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals","volume":"11","author":"Yeo","year":"2004","journal-title":"J Comput Biol"},{"key":"10.1124\/molpharm.124.000868_bib68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1124\/molpharm.124.000868_bib69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1101\/gr.234948.118","article-title":"Comprehensive, integrated, and phased whole-genome analysis of the primary ENCODE cell line K562","volume":"29","author":"Zhou","year":"2019","journal-title":"Genome Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.124.000868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:29:25Z","timestamp":1739957365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0026895X24000142"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.124.000868","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circumvention of Topoisomerase II\u03b1 Intron 19 Intronic Polyadenylation in Acquired Etoposide-Resistant Human Leukemia K562 Cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.124.000868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}